<DOC>
	<DOCNO>NCT02937675</DOCNO>
	<brief_summary>This clinical trial Phase 1-2 , open-label , sequential-group , dose-escalation cohort-expansion study evaluate safety , pharmacokinetics , pharmacodynamics , antitumor activity eFT508 . The study evaluate oral daily administration eFT508 . Treatment study subject evaluation perform 21-day cycle .</brief_summary>
	<brief_title>A Phase 1-2 Dose-Escalation Cohort-Expansion Study Oral eFT508 Subjects With Hematological Malignancies</brief_title>
	<detailed_description />
	<criteria>1 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 2 . Presence active hematological malignancy . 3 . Presence measurable disease . 4 . Hematological malignancy previously treat , relapse progress prior therapy , limited potential benefit currently available therapy include hematopoietic stem cell transplantation . 5 . At least 2 week post treatments/therapies time first dose . 6 . Adequate bone marrow function . 7 . Adequate hepatic function . 8 . Adequate renal function . 9 . Normal coagulation panel . 10 . Negative antiviral serology . 11 . Willingness use effective contraception . 1 . Central nervous system malignancy 2 . Gastrointestinal disease 3 . Significant cardiovascular disease 4 . Significant ECG abnormality . 5 . Ongoing risk bleed due active peptic ulcer disease , bleed diathesis requirement systemic anticoagulation 6 . Ongoing systemic bacterial , fungal , viral infection ( include upper respiratory tract infection ) 7 . Pregnancy breastfeed . 8 . Major surgery within 4 week start study therapy . 9 . Ongoing immunosuppressive therapy , include systemic enteric corticosteroid 10 . Use drug could prolong QT interval within 7 day start study therapy . 11 . Use drug might pose risk drugdrug interaction within 27 day start study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>small molecule inhibitor protein translation</keyword>
	<keyword>immunomodulator</keyword>
	<keyword>phase 1 dose escalation</keyword>
</DOC>